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Background: Dilated cardiomyopathy (DCM), the most common form of cardiomyopathy, is a leading cause of morbidity and mortality in the adult 
population. It is marked by ventricular enlargement and systolic dysfunction, and accounts for roughly 25 percent of the cases of heart failure in the 
United States. In ~50% cases of DCM, a defined etiology is not identified and the condition is deemed idiopathic. Clinical and molecular genetic 
data have indicated that many idiopathic DCM cases (~20-5%) result from an underlying familial genetic abnormality.
Methods: This study aims to uncover the molecular mechanisms behind the pathogenesis of DCM-induced heart failure by studying a transgenic 
mouse model that reconstitutes a human mutation - specifically an arginine-to-cysteine (R9C) mutation in phospholamban (PLN), a phosphoprotein 
that regulates calcium homeostasis. Our investigations focus on 3 different stages of disease in PLNR9C mice: preclinical (or Pre-DCM), DCM, and 
heart failure. To define molecules involved in the progression of these stages we are isolating myocytes and non-myocytes from PLNR9C hearts and 
generating RNA profiles. Differentially expressed RNAs are confirmed by immunostaining.
Results: PLNR9C hearts exhibit an increasing fibrotic phenotype from the Pre-DCM to DCM to heart failure stages, with proliferation of non-
myocytes occurring predominantly during the Pre-DCM stage. As fibrotic phenotype worsens, proliferation decreases. Growth differentiation factor 15 
(GDF15) and cartilage oligomeric matrix protein (COMP) RNAs are both significantly upregulated in PLNR9C mice during the DCM and heart failure 
stages.
Conclusions: Fibrosis in PLNR9C mouse hearts is inversely correlated with non-myocyte proliferation, suggesting that the fibrotic phenotype may 
be mediated by signals which increase collagen deposition rather than cell proliferation. GDF15 and COMP are both elevated during later stages of 
the disease and may play a role in the development of the fibrotic phenotype. Understanding the genetic mechanisms underlying the progression of 
DCM to heart failure, along with the role of fibrosis in this progression may help us to identify new molecular targets for therapy.
